Close
Help




JOURNAL

Biomarkers in Cancer

Trisomy 8 Acute Myeloid Leukemia Analysis Reveals New Insights of DNA Methylome with Identification of HHEX as Potential Diagnostic Marker

Submit a Paper


Biomarkers in Cancer 2015:7 1-6

Short Report

Published on 29 Jan 2015

DOI: 10.4137/BIC.S19614


Further metadata provided in PDF



Sign up for email alerts to receive notifications of new articles published in Biomarkers in Cancer

Abstract

Trisomy 8 acute myeloid leukemia (AML) is the commonest numerical aberration in AML. Here we present a global analysis of trisomy 8 AML using methylated DNA immunoprecipitation-sequencing (MeDIP-seq). The study is based on three diagnostic trisomy 8 AML and their parallel relapse status in addition to nine non-trisomic AML and four normal bone marrows (NBMs). In contrast to non-trisomic DNA samples, trisomy 8 AML showed a characteristic DNA methylation distribution pattern because an increase in the frequency of the hypermethylation signals in chromosome 8 was associated with an increase in the hypomethylation signals in the rest of the chromosomes. Chromosome 8 hypermethylation signals were found mainly in the CpG island (CGI) shores and interspersed repeats. Validating the most significant differentially methylated CGI (P = 7.88 × 10⁻¹¹) identified in trisomy 8 AML demonstrated a specific core region within the gene body of HHEX, which was significantly correlated with HHEX expression in both diagnostic and relapse trisomy 8 AMLs. Overall, the existence of extra chromosome 8 was associated with a global impact on the DNA methylation distribution with identification of HHEX gene methylation as a potential diagnostic marker for trisomy 8 AML.



Downloads

PDF  (1.69 MB PDF FORMAT)

RIS citation   (ENDNOTE, REFERENCE MANAGER, PROCITE, REFWORKS)

Supplementary Files 1  (552.45 KB DOC FORMAT)

BibTex citation   (BIBDESK, LATEX)

XML

PMC HTML


Sharing


What Your Colleagues Say About Biomarkers in Cancer
The editorial staff of Biomarkers in Cancer are very efficient and helpful.  I am happy to work with them.  I look forward to reviewing future manuscripts.
Dr Xi Liu (National Cancer Institute, National Institutes of Health, Bethesda, MD, USA )
More Testimonials

Quick Links


New article and journal news notification services
Email Alerts RSS Feeds
Facebook Google+ Twitter
Pinterest Tumblr YouTube